

Article title: The Effectiveness and Safety of Gemcitabine plus Nab-paclitaxel in Elderly Patients with Advanced Pancreatic Cancer: A Single-Center Retrospective Cohort Study

Journal name: Investigational New Drugs

Sae Ohwada, Akiko Todaka, Hiroshi Nakase, Hiromichi Shirasu, Takeshi Kawakami,
Satoshi Hamauchi, Takahiro Tsushima, Tomoya Yokota, Yusuke Onozawa, Hirofumi
Yasui, Kentaro Yamazaki

Corresponding Author:

Kentaro Yamazaki

Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumicho,
Suntougun, Shizuoka 411-8777, Japan

E-mail: k.yamazaki@scchr.jp

Online Resource 2. Subsequent therapies in both groups

	Monotherapy			<i>P</i> -value
	^a GnP	^b GEM	S-1	
	(<i>n</i> = 45)	(<i>n</i> = 31)	(<i>n</i> = 14)	
	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	
Subsequent therapy	25 (56)	17 (55)	6 (43)	0.75
S-1	19 (42)	15 (48)	0	0.001
^b GEM	0	0	6 (43)	<0.001
^c FOLFIRI	4 (9)	1 (3)	0	0.56
^d FOLFOX	1 (2)	0	0	1
^a GnP	0	1 (3)	0	0.50
Conversion surgery	1 (2)	0	0	1
Third-line therapy	6 (13)	5 (16)	1 (7)	0.84
Fourth-line therapy	0	2 (6)	0	0.25

^aGnP: gemcitabine plus nab-paclitaxel

^bGEM: gemcitabine

^cFOLFIRI: folinic acid (leucovorin), fluorouracil, and irinotecan

^dFOLFOX: folinic acid (leucovorin), fluorouracil, and oxaliplatin